» Articles » PMID: 36694478

Epidemiologic and Economic Modelling of Optimal COVID-19 Policy: Public Health and Social Measures, Masks and Vaccines in Victoria, Australia

Overview
Date 2023 Jan 25
PMID 36694478
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Identifying optimal COVID-19 policies is challenging. For Victoria, Australia (6.6 million people), we evaluated 104 policy packages (two levels of stringency of public health and social measures [PHSMs], by two levels each of mask-wearing and respirator provision during large outbreaks, by 13 vaccination schedules) for nine future SARS-CoV-2 variant scenarios.

Methods: We used an agent-based model to estimate morbidity, mortality, and costs over 12 months from October 2022 for each scenario. The 104 policies (each averaged over the nine future variant scenarios) were ranked based on four evenly weighted criteria: cost-effectiveness from (a) health system only and (b) health system plus GDP perspectives, (c) deaths and (d) days exceeding hospital occupancy thresholds.

Findings: More compared to less stringent PHSMs reduced cumulative infections, hospitalisations and deaths but also increased time in stage ≥3 PHSMs. Any further vaccination from October 2022 decreased hospitalisations and deaths by 12% and 27% respectively compared to no further vaccination and was usually a cost-saving intervention from a health expenditure plus GDP perspective. High versus low vaccine coverage decreased deaths by 15% and reduced time in stage ≥3 PHSMs by 20%. The modelled mask policies had modest impacts on morbidity, mortality, and health system pressure. The highest-ranking policy combination was more stringent PHSMs, two further vaccine doses (an Omicron-targeted vaccine followed by a multivalent vaccine) for ≥30-year-olds with high uptake, and promotion of increased mask wearing (but not Government provision of respirators).

Interpretation: Ongoing vaccination and PHSMs continue to be key components of the COVID-19 pandemic response. Integrated epidemiologic and economic modelling, as exemplified in this paper, can be rapidly updated and used in pandemic decision making.

Funding: Anonymous donation, University of Melbourne funding.

Citing Articles

Ongoing symptoms and functional impairment 12 weeks after testing positive for SARS-CoV-2 or influenza in Australia: an observational cohort study.

Brown M, Gerrard J, McKinlay L, Marquess J, Sparrow T, Andrews R BMJ Public Health. 2025; 1(1):e000060.

PMID: 40017858 PMC: 11812696. DOI: 10.1136/bmjph-2023-000060.


Predictive modelling of the effectiveness of vaccines against COVID-19 in Bogotá: Methodological innovation involving different variants and computational optimisation efficiency.

Espinosa O, White L, Bejarano V, Aguas R, Rincon D, Mora L Heliyon. 2024; 10(21):e39725.

PMID: 39559218 PMC: 11570482. DOI: 10.1016/j.heliyon.2024.e39725.


The Clinical Severity of COVID-19 Variants of Concern: Retrospective Population-Based Analysis.

Harrigan S, Velasquez Garcia H, Abdia Y, Wilton J, Prystajecky N, Tyson J JMIR Public Health Surveill. 2024; 10():e45513.

PMID: 39190434 PMC: 11387920. DOI: 10.2196/45513.


An overview of urban analytical approaches to combating the Covid-19 pandemic.

Yao X, Crooks A, Jiang B, Krisp J, Liu X, Huang H Environ Plan B Urban Anal City Sci. 2024; 50(5):1133-1143.

PMID: 38602958 PMC: 10160829. DOI: 10.1177/23998083231174748.


The re-emergence of influenza following the COVID-19 pandemic in Victoria, Australia, 2021 to 2022.

Pendrey C, Strachan J, Peck H, Aziz A, Moselen J, Moss R Euro Surveill. 2023; 28(37).

PMID: 37707981 PMC: 10687983. DOI: 10.2807/1560-7917.ES.2023.28.37.2300118.


References
1.
Behnood S, Shafran R, Bennett S, Zhang A, OMahoney L, Stephenson T . Persistent symptoms following SARS-CoV-2 infection amongst children and young people: A meta-analysis of controlled and uncontrolled studies. J Infect. 2021; 84(2):158-170. PMC: 8604800. DOI: 10.1016/j.jinf.2021.11.011. View

2.
Blakely T, Thompson J, Bablani L, Andersen P, Ait Ouakrim D, Carvalho N . Association of Simulated COVID-19 Policy Responses for Social Restrictions and Lockdowns With Health-Adjusted Life-Years and Costs in Victoria, Australia. JAMA Health Forum. 2022; 2(7):e211749. PMC: 8796885. DOI: 10.1001/jamahealthforum.2021.1749. View

3.
B Gilbert P, Montefiori D, McDermott A, Fong Y, Benkeser D, Deng W . Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2021; 375(6576):43-50. PMC: 9017870. DOI: 10.1126/science.abm3425. View

4.
Khoury D, Cromer D, Reynaldi A, Schlub T, Wheatley A, Juno J . Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021; 27(7):1205-1211. DOI: 10.1038/s41591-021-01377-8. View

5.
Nyberg T, Ferguson N, Nash S, Webster H, Flaxman S, Andrews N . Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet. 2022; 399(10332):1303-1312. PMC: 8926413. DOI: 10.1016/S0140-6736(22)00462-7. View